Enanta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ENTA) $9.25 -0.23 (-2.43%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$9.15▼$9.5750-Day Range$8.18▼$10.7852-Week Range$8.08▼$62.06Volume154,352 shsAverage Volume275,290 shsMarket Capitalization$194.80 millionP/E RatioN/ADividend YieldN/APrice Target$31.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside244.6% Upside$31.88 Price TargetShort InterestBearish7.72% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment-0.80Based on 4 Articles This WeekInsider TradingSelling Shares$118,459 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.44) to ($4.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector210th out of 946 stocksBiotechnology Industry11th out of 52 stocks 3.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.88, Enanta Pharmaceuticals has a forecasted upside of 244.6% from its current price of $9.25.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.72% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 12.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 1.8 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of -0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for ENTA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,459.00 in company stock.Percentage Held by Insiders12.70% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.44) to ($4.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Significant Increase in Short InterestNovember 27, 2023 | finance.yahoo.comHow Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%December 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 23, 2023 | benzinga.comEnanta Pharma Stock (NASDAQ:ENTA) Insider TradesNovember 22, 2023 | benzinga.comEnanta Pharma Stock (NASDAQ:ENTA) Earnings Dates and Earning CallsNovember 22, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Participate at Evercore ISI HealthCONx ConferenceNovember 21, 2023 | marketwatch.comEnanta Pharmaceuticals Shares Rise 21% After Slashing Spending GuidanceNovember 21, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Enanta PharmaDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 21, 2023 | finance.yahoo.comQ4 2023 Enanta Pharmaceuticals Inc Earnings CallNovember 21, 2023 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call TranscriptNovember 20, 2023 | benzinga.comRecap: Enanta Pharma Q4 EarningsNovember 20, 2023 | finance.yahoo.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ETNovember 20, 2023 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q4 and Full-Year Earnings Amid R&D FocusNovember 19, 2023 | msn.comEnanta Pharma Q4 2023 Earnings PreviewNovember 19, 2023 | markets.businessinsider.comEnanta Pharmaceuticals earnings preview: what to expectNovember 17, 2023 | finance.yahoo.comMILLENNIUM MANAGEMENT LLC Bolsters Portfolio with Enanta Pharmaceuticals Inc (ENTA) SharesNovember 16, 2023 | morningstar.comEnanta Pharmaceuticals Inc ENTANovember 13, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023October 30, 2023 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?October 23, 2023 | markets.businessinsider.comAnalyst Expectations for Enanta Pharma's FutureOctober 13, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV PipelineOctober 6, 2023 | finance.yahoo.comShareholders in Enanta Pharmaceuticals (NASDAQ:ENTA) have lost 87%, as stock drops 12% this past weekSeptember 19, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Enanta PharmaSeptember 17, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza ConferenceSeptember 7, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023August 13, 2023 | finance.yahoo.comThings Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's DowngradeSee More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/20/2023Today12/08/2023Next Earnings (Estimated)2/06/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees145Year FoundedN/APrice Target and Rating Average Stock Price Target$31.88 High Stock Price Target$87.00 Low Stock Price Target$14.00 Potential Upside/Downside+244.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($6.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,820,000.00 Net Margins-168.95% Pretax Margin-165.39% Return on Equity-52.23% Return on Assets-32.81% Debt Debt-to-Equity RatioN/A Current Ratio6.73 Quick Ratio6.73 Sales & Book Value Annual Sales$79.20 million Price / Sales2.46 Cash FlowN/A Price / Cash FlowN/A Book Value$10.29 per share Price / Book0.90Miscellaneous Outstanding Shares21,059,000Free Float18,385,000Market Cap$194.80 million OptionableOptionable Beta0.49 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 67)President, CEO & Director Comp: $1.23MMr. Paul J. Mellett Jr. (Age 68)Senior VP of Finance & Administration and CFO Comp: $650.94kDr. Yat Sun Or Ph.D. (Age 71)Senior VP of Research & Development and Chief Scientific Officer Comp: $720.16kMr. Nathaniel S. Gardiner J.D. (Age 69)Senior VP, General Counsel & Secretary Comp: $657.95kDr. Scott T. Rottinghaus M.D. (Age 49)Senior VP & Chief Medical Officer Comp: $616.73kMs. Jennifer VieraSenior Director of Investor Relations & Corporate CommunicationsMs. Tara Lynn Kieffer Ph.D. (Age 45)Senior Vice President of New Product Strategy & Development Comp: $496.85kMr. Brendan Luu (Age 48)Senior Vice President of Business Development Comp: $535.8kMore ExecutivesKey CompetitorsCorMedixNASDAQ:CRMDArcutis BiotherapeuticsNASDAQ:ARQTFoghorn TherapeuticsNASDAQ:FHTXAkebia TherapeuticsNASDAQ:AKBASilverback TherapeuticsNASDAQ:SBTXView All CompetitorsInsiders & InstitutionsJay R LulySold 7,230 sharesTotal: $69,624.90 ($9.63/share)Paul J MellettSold 2,412 sharesTotal: $23,227.56 ($9.63/share)Brendan LuuSold 2,125 sharesTotal: $20,463.75 ($9.63/share)Scott T RottinghausSold 534 sharesTotal: $5,142.42 ($9.63/share)Deutsche Bank AGBought 1,383 shares on 11/24/2023Ownership: 0.049%View All Insider TransactionsView All Institutional Transactions ENTA Stock Analysis - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price target for 2024? 8 Wall Street analysts have issued 1-year target prices for Enanta Pharmaceuticals' stock. Their ENTA share price targets range from $14.00 to $87.00. On average, they expect the company's share price to reach $31.88 in the next year. This suggests a possible upside of 244.6% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2023? Enanta Pharmaceuticals' stock was trading at $46.52 at the beginning of 2023. Since then, ENTA stock has decreased by 80.1% and is now trading at $9.25. View the best growth stocks for 2023 here. Are investors shorting Enanta Pharmaceuticals? Enanta Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,510,000 shares, an increase of 12.7% from the October 31st total of 1,340,000 shares. Based on an average trading volume of 459,800 shares, the days-to-cover ratio is presently 3.3 days. Approximately 7.7% of the company's shares are sold short. View Enanta Pharmaceuticals' Short Interest. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.11) by $0.78. The biotechnology company had revenue of $18.93 million for the quarter, compared to analyst estimates of $17.93 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 52.23% and a negative net margin of 168.95%. During the same quarter in the previous year, the company posted ($1.27) earnings per share. What ETF holds Enanta Pharmaceuticals' stock ? ETFMG Treatments Testing and Advancements ETF holds 5,945 shares of ENTA stock, representing 0.75% of its portfolio. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (9.97%), Northern Trust Corp (4.56%), Krensavage Asset Management LLC (3.49%), Assenagon Asset Management S.A. (3.00%), Acadian Asset Management LLC (2.61%) and Jacobs Levy Equity Management Inc. (1.64%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ENTA) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.